Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacists | 6 | 2023 | 126 | 0.990 |
Why?
|
| Community Health Centers | 3 | 2013 | 92 | 0.770 |
Why?
|
| Public Health | 2 | 2013 | 188 | 0.700 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2007 | 216 | 0.630 |
Why?
|
| Telemedicine | 1 | 2023 | 323 | 0.590 |
Why?
|
| Exercise | 4 | 2013 | 939 | 0.580 |
Why?
|
| Anticoagulants | 5 | 2020 | 495 | 0.580 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2013 | 226 | 0.570 |
Why?
|
| Medicare Part D | 1 | 2017 | 36 | 0.550 |
Why?
|
| Cost Savings | 1 | 2017 | 54 | 0.550 |
Why?
|
| Primary Health Care | 2 | 2013 | 690 | 0.530 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 690 | 0.500 |
Why?
|
| Hypercholesterolemia | 2 | 2007 | 70 | 0.490 |
Why?
|
| Polypharmacy | 1 | 2016 | 61 | 0.490 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2006 | 24 | 0.480 |
Why?
|
| Pancreatitis | 1 | 2016 | 97 | 0.470 |
Why?
|
| Aspirin | 2 | 2013 | 171 | 0.470 |
Why?
|
| Venous Thromboembolism | 4 | 2020 | 149 | 0.430 |
Why?
|
| Ticlopidine | 3 | 2013 | 49 | 0.420 |
Why?
|
| Warfarin | 2 | 2014 | 111 | 0.410 |
Why?
|
| Antipsychotic Agents | 1 | 2016 | 301 | 0.410 |
Why?
|
| Stroke | 3 | 2013 | 1191 | 0.310 |
Why?
|
| Anticholesteremic Agents | 1 | 2007 | 35 | 0.260 |
Why?
|
| Hemorrhage | 6 | 2018 | 267 | 0.260 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2006 | 168 | 0.230 |
Why?
|
| Humans | 26 | 2023 | 63149 | 0.230 |
Why?
|
| Atrial Fibrillation | 1 | 2013 | 837 | 0.230 |
Why?
|
| Angina, Unstable | 1 | 2004 | 58 | 0.230 |
Why?
|
| Coronary Disease | 1 | 2006 | 246 | 0.230 |
Why?
|
| Tyrosine | 1 | 2004 | 94 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2018 | 733 | 0.220 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 2023 | 3 | 0.210 |
Why?
|
| Anemia, Hemolytic | 1 | 2023 | 12 | 0.210 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 165 | 0.210 |
Why?
|
| Quinolones | 1 | 2023 | 29 | 0.210 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2003 | 20 | 0.200 |
Why?
|
| Computers, Handheld | 1 | 2003 | 38 | 0.200 |
Why?
|
| Anemia, Sickle Cell | 1 | 2023 | 63 | 0.200 |
Why?
|
| Coronary Artery Disease | 3 | 2016 | 310 | 0.200 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 90 | 0.190 |
Why?
|
| Urban Population | 1 | 2023 | 193 | 0.190 |
Why?
|
| Documentation | 1 | 2003 | 128 | 0.190 |
Why?
|
| Diabetes Mellitus | 2 | 2008 | 537 | 0.170 |
Why?
|
| Pharmaceutical Services | 2 | 2017 | 33 | 0.160 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6595 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 174 | 0.140 |
Why?
|
| Pandemics | 1 | 2023 | 672 | 0.140 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 452 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 913 | 0.140 |
Why?
|
| Pharmacies | 1 | 2017 | 36 | 0.140 |
Why?
|
| Male | 11 | 2020 | 29717 | 0.130 |
Why?
|
| Rivaroxaban | 2 | 2014 | 19 | 0.130 |
Why?
|
| Dabigatran | 2 | 2014 | 20 | 0.130 |
Why?
|
| Pyridones | 2 | 2014 | 40 | 0.130 |
Why?
|
| Pyrazoles | 2 | 2014 | 78 | 0.130 |
Why?
|
| Female | 11 | 2020 | 32709 | 0.130 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 473 | 0.120 |
Why?
|
| Hospitalization | 3 | 2020 | 1356 | 0.120 |
Why?
|
| Benzazepines | 1 | 2016 | 21 | 0.120 |
Why?
|
| Massachusetts | 3 | 2017 | 2073 | 0.120 |
Why?
|
| Adult | 7 | 2023 | 16736 | 0.110 |
Why?
|
| Aged | 6 | 2017 | 14333 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 194 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2016 | 165 | 0.110 |
Why?
|
| Dipyridamole | 1 | 2013 | 17 | 0.110 |
Why?
|
| Schizophrenia | 1 | 2016 | 265 | 0.100 |
Why?
|
| Databases, Bibliographic | 1 | 2013 | 9 | 0.100 |
Why?
|
| beta-Alanine | 1 | 2013 | 8 | 0.100 |
Why?
|
| Thiophenes | 1 | 2013 | 29 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 463 | 0.100 |
Why?
|
| Morpholines | 1 | 2013 | 88 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2013 | 54 | 0.100 |
Why?
|
| Proline | 1 | 2013 | 44 | 0.100 |
Why?
|
| Fees and Charges | 1 | 2012 | 17 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2013 | 163 | 0.100 |
Why?
|
| Oligopeptides | 1 | 2013 | 132 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2016 | 5625 | 0.100 |
Why?
|
| Protease Inhibitors | 1 | 2013 | 102 | 0.090 |
Why?
|
| Anti-Ulcer Agents | 1 | 2011 | 9 | 0.090 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 88 | 0.090 |
Why?
|
| Students, Pharmacy | 1 | 2011 | 13 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1092 | 0.090 |
Why?
|
| Ambulatory Care Facilities | 1 | 2012 | 105 | 0.090 |
Why?
|
| Double-Blind Method | 1 | 2013 | 737 | 0.090 |
Why?
|
| Middle Aged | 7 | 2016 | 17480 | 0.090 |
Why?
|
| Inappropriate Prescribing | 1 | 2011 | 66 | 0.090 |
Why?
|
| Community Health Services | 1 | 2012 | 128 | 0.090 |
Why?
|
| Motor Activity | 1 | 2012 | 346 | 0.080 |
Why?
|
| Sex Factors | 1 | 2012 | 978 | 0.080 |
Why?
|
| Education, Pharmacy, Graduate | 1 | 2009 | 4 | 0.080 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2009 | 3 | 0.080 |
Why?
|
| Medical Waste Disposal | 1 | 2009 | 4 | 0.080 |
Why?
|
| Risk Factors | 3 | 2013 | 5331 | 0.080 |
Why?
|
| Mental Disorders | 1 | 2016 | 788 | 0.070 |
Why?
|
| Age Factors | 1 | 2012 | 1559 | 0.070 |
Why?
|
| Health Promotion | 1 | 2012 | 494 | 0.070 |
Why?
|
| Program Development | 1 | 2009 | 207 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 108 | 0.070 |
Why?
|
| Young Adult | 2 | 2016 | 4673 | 0.070 |
Why?
|
| Adolescent | 2 | 2016 | 6229 | 0.070 |
Why?
|
| Cooperative Behavior | 1 | 2008 | 222 | 0.060 |
Why?
|
| United States | 2 | 2017 | 7824 | 0.060 |
Why?
|
| Child | 1 | 2016 | 4520 | 0.060 |
Why?
|
| Rhabdomyolysis | 1 | 2006 | 23 | 0.060 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 255 | 0.060 |
Why?
|
| Poverty | 1 | 2008 | 296 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 180 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 298 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 860 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2004 | 34 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2004 | 106 | 0.050 |
Why?
|
| Acute Disease | 1 | 2006 | 671 | 0.050 |
Why?
|
| Pyruvate Metabolism, Inborn Errors | 1 | 2023 | 3 | 0.050 |
Why?
|
| Pyruvate Kinase | 1 | 2023 | 11 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 755 | 0.050 |
Why?
|
| Hemolysis | 1 | 2023 | 40 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2006 | 306 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 1 | 2003 | 40 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2011 | 3270 | 0.050 |
Why?
|
| Research Design | 1 | 2006 | 573 | 0.050 |
Why?
|
| Incidence | 1 | 2006 | 1372 | 0.050 |
Why?
|
| Registries | 1 | 2006 | 886 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 734 | 0.040 |
Why?
|
| Peptides | 1 | 2004 | 574 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 862 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 834 | 0.040 |
Why?
|
| Home Care Services | 1 | 2020 | 98 | 0.040 |
Why?
|
| Premedication | 1 | 2018 | 19 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2020 | 510 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2016 | 150 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 321 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 369 | 0.030 |
Why?
|
| Ribavirin | 1 | 2013 | 23 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2013 | 25 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 42 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2013 | 103 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2013 | 117 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2012 | 37 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 168 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 700 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2011 | 160 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 317 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2009 | 5 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 2009 | 24 | 0.020 |
Why?
|
| Environmental Pollution | 1 | 2009 | 14 | 0.020 |
Why?
|
| Training Support | 1 | 2009 | 20 | 0.020 |
Why?
|
| Drug Industry | 1 | 2009 | 39 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2011 | 358 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 157 | 0.020 |
Why?
|
| Community Participation | 1 | 2008 | 46 | 0.020 |
Why?
|
| Heart Failure | 1 | 2016 | 912 | 0.020 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2007 | 25 | 0.020 |
Why?
|
| Pharmaceutical Preparations | 1 | 2009 | 123 | 0.020 |
Why?
|
| Data Collection | 1 | 2009 | 384 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 563 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 208 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2007 | 768 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 172 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 2560 | 0.010 |
Why?
|
| Thrombosis | 1 | 2007 | 199 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2009 | 590 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 5429 | 0.010 |
Why?
|